Back to Search
Start Over
Erythrocyte membrane fluidity: A novel biomarker of residual cardiovascular risk in type 2 diabetes.
- Source :
- European Journal of Clinical Investigation; Mar2024, Vol. 54 Issue 3, p1-12, 12p
- Publication Year :
- 2024
-
Abstract
- Aims: Improving the composition of circulating fatty acids (FA) leads to a reduction in cardiovascular diseases (CVD) in high‐risk individuals. The membrane fluidity of red blood cells (RBC), which reflects circulating FA status, may be a valid biomarker of cardiovascular (CV) risk in type 2 diabetes (T2D). Methods: Red blood cell membrane fluidity, quantified as general polarization (GP), was assessed in 234 subjects with T2D, 86 with prior major CVD. Based on GP distribution, a cut‐off of.445 was used to divide the study cohort into two groups: the first with higher GP, called GEL, and the second, defined as lower GP (LGP). Lipidomic analysis was performed to evaluate FA composition of RBC membranes. Results: Although with comparable CV risk factors, the LGP group had a greater percentage of patients with major CVD than the GEL group (40% vs 24%, respectively, p <.05). Moreover, in a logistic regression analysis, a lower GP value was independently associated with the presence of macrovascular complications. Lipidomic analysis showed a clear shift of LGP membranes towards a pro‐inflammatory condition due to higher content of arachidonic acid and increased omega 6/omega 3 index. Conclusions: Increased membrane fluidity is associated with a higher CV risk in subjects with T2D. If confirmed in prospective studies, membrane fluidity could be a new biomarker for residual CV risk assessment in T2D. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00142972
- Volume :
- 54
- Issue :
- 3
- Database :
- Complementary Index
- Journal :
- European Journal of Clinical Investigation
- Publication Type :
- Academic Journal
- Accession number :
- 175417700
- Full Text :
- https://doi.org/10.1111/eci.14121